Released Jun 14, 2021, after the close
10-Q filed Jun 14, 2021, 45 days after period end · 0001654954-21-006857
Q2 2021 · 10-Q
Revenue$5.04M$5.04M −10.7% vs Q2 2020+12.3% vs Q1 2021
Net Income$240.27K$240.27K −65.1% vs Q2 2020−10.4% vs Q1 2021
EPS, diluted—
Gross Profit$1,290,872−30.9%
Operating Income$264,779−63.2%
Operating Cash Flow-$1,185,418N/M
Free Cash Flowderived-$1,187,466N/M
Margins · derived
Gross margin25.6%−7.5 pt vs Q2 2020
Operating margin5.3%−7.5 pt vs Q2 2020
Net margin4.8%−7.4 pt vs Q2 2020
What the release said
The release
Same quarter
| Metric | Q2 2021 | Q2 2020 | Q2 2019 | Q2 2018 |
|---|---|---|---|---|
| Revenue | $5.04M | $5.65M | $5.15M | $3.77M |
| Net Income | $240.27K | $687.56K | $707.48K | -$128.35K |
| EPS Diluted | — | — | — | -$0.01 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pharma-Bio Serv, Inc. · CIK 1304161 · Engraved from SEC EDGAR